Added to YB: 2025-10-07
Pitch date: 2025-10-03
NVO [bullish]
Novo Nordisk A/S
-19.11%
current return
Author Info
Undervalued-Shares.com finds world class companies trading at low prices. Visit the website.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 380.00
Price Target
120.00 (-61%)
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
3 investment ideas from last night’s reader dinner - Novo Nordisk A/S
NVO: Weight loss drug duopoly w/ Eli Lilly but trades at 1/3 the multiples despite comparable fundamentals. Stock fell from DKK 1,000 to <DKK 400 after CagriSema trial showed 23% vs 25% expected weight loss, causing CEO departure. New CagriSema trial underway. 50-100% upside potential to LLY valuation parity.
Read full article (2 min)